ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020
Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 77 citations in OpenAlex.
- The Role of PET Tracers in Small-Cell Prostate Cancer (SCPC): An Overview in Clinical and Preclinical Settings.Cancers · 2026Review
- A dual-tracer approach for enhanced nodal staging in prostate cancer: the role of [European journal of nuclear medicine and molecular imaging · 2026Article
- Head-to-head comparison betweenJournal of translational medicine · 2026Article
- Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology.International journal of molecular sciences · 2025Review
- Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.Nature reviews. Urology · 2025Review
- Head-to-head comparison ofFrontiers in oncology · 2025Article
- Review
- From biology to the clinic - exploring liver metastasis in prostate cancer.Nature reviews. Urology · 2024Review
- [Clinical Value of Dual Tracer PET Imaging WithSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Article
- Prostate Specific Membrane Antigen Expression in a Syngeneic Breast Cancer Mouse Model.Molecular imaging and biology · 2024Article
- Paraneoplastic syndrome as a manifestation small cell carcinoma of the prostate: a rare presentation within a rare tumor.Internal and emergency medicine · 2024Article
- A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer.Molecular cancer therapeutics · 2024Article
- Discordant Molecular Imaging Findings with 2-[Nuclear medicine and molecular imaging · 2024Article
- CDC6 may serve as an indicator of lung adenocarcinoma prognosis and progression based on TCGA and GEO data mining and experimental analyses.Oncology reports · 2024Article
- YAP Promotes Chemoresistance to 5-FU in Colorectal Cancer Through mTOR/GLUT3 Axis.Journal of Cancer · 2024Article
- Molecular imaging reveals the heterogeneous progression of tumor cells and tumor stroma: a practice of FDG PET and FAPI PET in diagnosing PSMA-negative bone metastases of progressive prostate cancer.American journal of nuclear medicine and molecular imaging · 2024Article
- Article
- Metabolically regulated lineages in prostate cancer.Nature cell biology · 2023Article
- PSMA PET imaging in the diagnosis and management of prostate cancer.Abdominal radiology (New York) · 2023Review
- PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 8 institutions in 4 countries.
Funding
Abstract
Although the incidence of de novo neuroendocrine prostate cancer (PC) is rare, recent data suggest that low expression of prostate-specific membrane antigen (PSMA) is associated with a spectrum of neuroendocrine hallmarks and androgen receptor (AR) suppression in PC. Previous clinical reports indicate that PCs with a phenotype similar to neuroendocrine tumors can be more amenable to imaging by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.